Even though recommendations suggest to evaluate EMT using different techniques and markers (flow cytometry, Western blot, immunohistochemistry, immunofluorescence), the research on EMT using human biopsies from patients with breast cancer is limited to the use of immunofluorescence with the use of E‐cadherin and vimentin in the majority of the studies [38]; (d) EMT is dynamic over time, and our results might not reflect the reality, since we only collected samples at diagnosis and after surgery. The gene discussed is CDH1; the disease is breast carcinoma.